BD secures BARDA funds for development of COVID-19 test

2019 08 20 21 56 4986 Becton Aacc 2019 400

Becton Dickinson (BD) has secured $24.7 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop diagnostic tests for COVID-19.

Under terms of the deal, BARDA will extend its support to BD by up to $40.3 million for the development and U.S. Food and Drug Administration (FDA) clearance of five new tests:

  • A rapid, point-of-care test that identifies SARS-CoV-2, influenza A, and influenza B and distinguishes them.
  • A molecular polymerase chain reaction (PCR) test for hospitals that identifies SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus and distinguishes them.
  • A molecular PCR test for hospitals or moderate-throughput laboratories to detect and distinguish between SARS-CoV-1, Middle East Respiratory Syndrome (MERS), seasonal coronaviruses, and new coronaviruses.
  • A molecular PCR test for high-throughput labs that identifies and distinguishes between SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus.
  • A molecular PCR test for high-throughput labs that detects and distinguishes between SARS-CoV-1, Middle East Respiratory Syndrome (MERS), seasonal coronaviruses and emerging coronaviruses.

The tests will help healthcare workers to make better treatment decisions, BD said.

Page 1 of 16
Next Page